Goldman Sachs and EQT AB expand in the medical sector

July 06, 2021
Goldman Sachs and EQT AB expand in the medical sector

The week begins with news about a new acquisition

Goldman Sachs Group’s investment arm and the Swedish private equity firm EQT AB revealed they would buy Parexel International – a clinical research company – from Pamplona Capital Management for $8.5 billion, including debt.

According to Bloomberg, Parexel drew interest from about ten parties, including various private-equity firms and drug distributor AmerisourceBergen. The company was founded in 1982, and it’s headed by Jamie Macdonald, a former adviser to EQT. He will remain chief executive after the deal closes.

For Goldman Sachs, this is not the first investment in the medical field. Its Asset Management oversees, among others, a manager of optometry services it purchased in 2019 and Datavant – a health care data-management company it invested in last month. The arm has roughly $2 trillion under management.

EQT oversees $79 billion in assets and focuses on real estate, technology, infrastructure, and healthcare.


This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.

Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of

Recently Added

Most Affected Instruments

goldmans chart
amerisource chart